A Phase 1/2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis.

Trial Profile

A Phase 1/2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs MIS 416 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Innate Immunotherapeutics
  • Most Recent Events

    • 28 Apr 2017 Results (n=102) assessing effect of mutations in the gene NFKBIA on patients response to MIS416 using patient data from NCT02228213 and NCT01191996 trials, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of profiling the kynurenine pathway and effect of MIS416 on Kynurenine pathway, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results (n=11) assessing neurological status of SPMS patients, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top